Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10-15 d, with a mean reduction of >or=1.6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach.
Fätkenheuer
Gerd
G
Department of Internal Medicine, Division of Infectious Diseases, Haus 11, University of Cologne, Joseph-Stelzmann-Strasse 9, D-50924 Cologne, Germany.
Pozniak
Anton L
AL
Johnson
Margaret A
MA
Plettenberg
Andreas
A
Staszewski
Schlomo
S
Hoepelman
Andy I M
AI
Saag
Michael S
MS
Goebel
Frank D
FD
Rockstroh
Jürgen K
JK
Dezube
Bruce J
BJ
Jenkins
Tim M
TM
Medhurst
Christine
C
Sullivan
John F
JF
Ridgway
Caroline
C
Abel
Samantha
S
James
Ian T
IT
Youle
Mike
M
van der Ryst
Elna
E
D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D019540:Area Under Curve; D065100:CCR5 Receptor Antagonists; D017322:Clinical Trials, Phase II as Topic; D003510:Cyclohexanes / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D000077592:Maraviroc; D012367:RNA, Viral / Q000097:blood; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D019562:Viral Load / Q000706:statistics & numerical data
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D012367:RNA, Viral; D014230:Triazoles; D000077592:Maraviroc